These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28554416)
21. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Diaz NL; Waters CH Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137 [TBL] [Abstract][Full Text] [Related]
22. Nonmotor symptoms in essential tremor: Comparison with Parkinson's disease and normal control. Lee SM; Kim M; Lee HM; Kwon KY; Koh SB J Neurol Sci; 2015 Feb; 349(1-2):168-73. PubMed ID: 25641389 [TBL] [Abstract][Full Text] [Related]
24. Medical management of advanced Parkinson's disease. Goudreau JL Clin Geriatr Med; 2006 Nov; 22(4):753-72, v. PubMed ID: 17000334 [TBL] [Abstract][Full Text] [Related]
25. Parkinson's disease: Diagnosis and appreciation of comorbidities. Deeb W; Nozile-Firth K; Okun MS Handb Clin Neurol; 2019; 167():257-277. PubMed ID: 31753136 [TBL] [Abstract][Full Text] [Related]
26. A Pragmatic Approach to the Perioperative Management of Parkinson's Disease. Lenka A; Mittal SO; Lamotte G; Pagan FL Can J Neurol Sci; 2021 May; 48(3):299-307. PubMed ID: 32959743 [TBL] [Abstract][Full Text] [Related]
27. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. Faulkner MA Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891 [TBL] [Abstract][Full Text] [Related]
28. Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment. Zhu M; Li M; Ye D; Jiang W; Lei T; Shu K J Neurosci Res; 2016 Aug; 94(8):685-92. PubMed ID: 26948282 [TBL] [Abstract][Full Text] [Related]
29. Device-Aided Treatment Strategies in Advanced Parkinson's Disease. Timpka J; Nitu B; Datieva V; Odin P; Antonini A Int Rev Neurobiol; 2017; 132():453-474. PubMed ID: 28554418 [TBL] [Abstract][Full Text] [Related]
37. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. Smith KM; Eyal E; Weintraub D; JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207 [TBL] [Abstract][Full Text] [Related]
38. The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. Stocchi F; Stirpe P J Neural Transm (Vienna); 2014 Aug; 121 Suppl 1():S79-83. PubMed ID: 24990308 [TBL] [Abstract][Full Text] [Related]
39. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity. Mehndiratta M; Garg RK; Pandey S J Assoc Physicians India; 2011 May; 59():302-8, 313. PubMed ID: 21751608 [TBL] [Abstract][Full Text] [Related]
40. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease. Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]